Envista’s (NVST) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Envista (NYSE:NVST) in a report released on Tuesday,Benzinga reports.

NVST has been the topic of several other research reports. Mizuho began coverage on Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Piper Sandler lifted their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Jefferies Financial Group boosted their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Finally, Robert W. Baird lifted their target price on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Envista has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Stock Down 3.3 %

Shares of NYSE NVST opened at $20.68 on Tuesday. The stock has a market capitalization of $3.56 billion, a P/E ratio of -3.19, a PEG ratio of 1.27 and a beta of 1.34. Envista has a one year low of $15.15 and a one year high of $23.00. The firm’s 50 day simple moving average is $20.18 and its two-hundred day simple moving average is $19.62. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, analysts expect that Envista will post 1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Polar Asset Management Partners Inc. increased its position in shares of Envista by 27.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 1,914,799 shares of the company’s stock valued at $36,936,000 after buying an additional 417,549 shares during the period. Brickwood Asset Management LLP purchased a new position in shares of Envista during the 4th quarter worth approximately $40,037,000. Vise Technologies Inc. grew its holdings in shares of Envista by 14.7% during the 4th quarter. Vise Technologies Inc. now owns 16,016 shares of the company’s stock worth $309,000 after acquiring an additional 2,056 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Envista by 15.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 492,736 shares of the company’s stock worth $9,505,000 after acquiring an additional 67,234 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of Envista by 66.6% in the 4th quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock valued at $922,000 after purchasing an additional 19,100 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.